Page 2 - Davide Olson News Today

/PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological...

/PRNewswire/ -- NemaLife Inc.,a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at...

/PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological...

/PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological...

/PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for serious psychiatric and...

/PRNewswire/ -- Delix Therapeutics (the "Company") is honored to have been named by Fierce Biotech as one of 2021s "Fierce 15" biotechnology companies,...

Published: Jul 02, 2021 By Alex Keown OcuTerra Therapeutics – David J. Tanzer was named Chief Medical Officer and Executive Vice President, Clinical and Medical Affairs for Boston-based OcuTerra. Prior to joining OcuTerra, Tanzer served as Global Executive Medical Director in the Novartis ophthalmology franchise. Before that, he served as the CMO at Abbott Medical Optics. He also led the Navy Refractive Surgery Program in San Diego, participating as principal or co-investigator in ove...

/PRNewswire/ -- Delix Therapeutics (the "Company"), a preclinical neuroscience company developing novel disease-modifying therapeutics for serious psychiatric...

Psychedelic Analog Restores Calm (and Neural Circuits) in Stressed Out Mice May 25, 2021 A non-hallucinogenic psychedelic analog that has shown promise against addiction and depression may have yet another potential benefit. It may reverse stress-induced harms such as anxiety and disrupted neural activities. This possibility is being explored by scientists based at the University of California (UC), Santa Cruz. They recently reported that an ibogaine-like drug—that is, a drug structurally sim...

Delix Therapeutics Retains KCSA Strategic Communications KCSA to provide integrated public and investor relations counsel News provided by Share this article Share this article BOSTON, May 19, 2021 /PRNewswire/ -- Delix Therapeutics (the "Company"), a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced that it has retained KCSA Strategic Communications, a leading integrated communications firm, as its a...